This collaboration is set to marry the formidable capabilities of both entities, granting broader access to state-of-the-art genomic technologies, unparalleled bioinformatics services, and groundbreaking diagnostics solutions.

Strand Life Sciences, with its headquarters nestled in Bangalore, India, stands out as a beacon in the life sciences technology domain. Its proficiency spans across bioinformatics, laboratory assays, clinical research, and software development, serving an extensive global clientele. This alliance seeks to harness these capabilities to enhance and broaden the application of precision medicine on a global scale.

Ramesh Hariharan, CEO and Co-Founder of Strand, expressed enthusiasm over the partnership with SOPHiA GENETICS, highlighting the combined bioinformatics expertise as a key driver for enabling global partners to deliver cutting-edge precision medicine, thereby elevating patient care standards.

Central to this strategic partnership is the utilization of both companies’ advanced bioinformatics acumen to improve the accuracy of healthcare data analysis and foster data-driven decision-making worldwide. SOPHiA GENETICS will extend support through its decentralized SOPHiA DDM™ Platform, while Strand will contribute its curated variant databases and bioinformatics solutions expertise. The collaboration will also focus on strategic test co-development and other initiatives aimed at enhancing health outcomes in India and beyond.

Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS, echoed the sentiment of a unified vision between Strand and SOPHiA GENETICS to ameliorate patient health outcomes through precision medicine. He stressed the importance of healthcare organizations being able to process diverse data efficiently and accurately, to expedite and optimize treatments for cancers and rare diseases. This partnership, according to Camblong, is poised to catalyze innovation in the field.

At the heart of this collaboration is the SOPHiA DDM™ Platform, designed for the computation of a myriad of genomic variants and the refinement of machine learning algorithms. By combining their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand are set to significantly enhance their value propositions in the healthcare sector, marking a new era in the pursuit of global precision medicine.